New AI-Driven Tool by PhaseV and iOMEDICO to Boost Phase 3 Cancer Trial Success

PhaseV, a leader in applying causal machine learning to clinical trials, has teamed up with iOMEDICO, a clinical research organization with a focus on oncology and hematology, to introduce a novel virtual analytical framework. This solution is aimed at pharmaceutical and biotechnology firms looking to enhance and mitigate risks in phase 3 oncology trials.

Many cancer drug candidates that show promise in phase 2 studies do not succeed in phase 3 due to various factors such as the inability to demonstrate significant benefits over existing treatments, differing endpoint criteria, and a broader patient demographic in phase 3.

The innovative solution integrates iOMEDICO's extensive real-world oncology data with PhaseV's causal-ML technology to tackle these issues. It offers tools for enriching standard of care comparisons, modeling endpoints, and identifying subgroups, which can help sponsors gain a clearer understanding of their drug's performance and refine phase 3 trial designs for better results.

Michael Pröschel, CEO of iOMEDICO, highlighted the importance of this collaboration, stating that the integration of real-world data with phase 2 outcomes provides essential insights into how new treatments impact diverse patient groups. He emphasized that the combined database and PhaseV's technology represent a significant advancement in phase 3 oncology trials, facilitating the introduction of new therapies to the market.

iOMEDICO's real-world oncology data, which encompasses biomarkers from over 50,000 patients, is crucial for PhaseV's technology. This data, along with phase 2 trial specifics, helps in understanding oncologic subpopulations deeply, aiding the simulation and design of successful phase 3 trials and bolstering sponsors' confidence.

Dr. Raviv Pryluk, CEO and Co-founder of PhaseV, noted the unique hurdles oncology drug candidates face in phase 3 trials. The virtual platform created with iOMEDICO's data simulates drug performance in phase 3, helping promising drugs to realize their full potential and offering new treatment options for cancer patients.

PhaseV's technology aids in de-risking and optimizing trials by analyzing numerous factors that could affect a trial, from recruitment rates to patient responses to therapy. The causal ML solution uncovers hidden patterns in clinical data, allowing for better endpoint assessments and patient subgroup analysis to enhance trial outcomes.

iOMEDICO is renowned for its oncology clinical grade patient registries, with over 50,000 longitudinal patient datasets covering a wide range of solid and hematologic tumors. Founded by oncologists, the organization specializes in translating clinical inquiries into practical trial designs to enhance patient care, collecting detailed data from more than 6,000 new oncology patients annually.

PhaseV harnesses advanced causal inference and machine learning to uncover hidden signals in clinical data, providing actionable insights for planning optimal next steps. The company's technology supports the design and execution of adaptive clinical trials, improving efficiency and success rates, and driving paradigm shifts in clinical trials to deliver new treatments to patients more effectively.

Both companies are dedicated to advancing clinical trials and improving patient outcomes, utilizing cutting-edge technology and extensive data to revolutionize the approach to oncology treatments.